CN113897376B - 一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株 - Google Patents

一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株 Download PDF

Info

Publication number
CN113897376B
CN113897376B CN202111173227.2A CN202111173227A CN113897376B CN 113897376 B CN113897376 B CN 113897376B CN 202111173227 A CN202111173227 A CN 202111173227A CN 113897376 B CN113897376 B CN 113897376B
Authority
CN
China
Prior art keywords
leu
ser
thr
newcastle disease
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111173227.2A
Other languages
English (en)
Other versions
CN113897376A (zh
Inventor
于晓慧
王静静
刘华雷
李峥
舒波
李阳
蒋文明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHINA ANIMAL HEALTH AND EPIDEMIOLOGY CENTER
Original Assignee
CHINA ANIMAL HEALTH AND EPIDEMIOLOGY CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHINA ANIMAL HEALTH AND EPIDEMIOLOGY CENTER filed Critical CHINA ANIMAL HEALTH AND EPIDEMIOLOGY CENTER
Priority to CN202111173227.2A priority Critical patent/CN113897376B/zh
Publication of CN113897376A publication Critical patent/CN113897376A/zh
Application granted granted Critical
Publication of CN113897376B publication Critical patent/CN113897376B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161Methods of inactivation or attenuation
    • C12N2760/18162Methods of inactivation or attenuation by genetic engineering
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明提供一种HN蛋白突变的基因VII型新城疫病毒重组疫苗株,其中用于构建基因VII型新城疫病毒重组疫苗株的过程中使用的基因片段包含了毒性致弱的基因VII.2亚型新城疫病毒的囊膜糖蛋白F蛋白基因和HN蛋白基因。本发明提供的基因VII型新城疫病毒重组疫苗株在鸡胚中具有高生长滴度和低致病力的生物学特性,遗传稳定,对新城病毒具有良好的免疫保护效果,并能有效抑制排毒,能够用于防控目前流行的基因VII型新城疫病毒,具有广阔的应用前景。

Description

一种HN蛋白突变的基因VII型新城疫病毒重组疫苗株
技术领域
本发明属于兽用生物制品技术领域,具体涉及一种HN蛋白突变的基因VII型新城疫病毒重组疫苗株及其构建方法和应用。
背景技术
新城疫(Newcastle disease,ND)是由新城疫病毒(Newcastle disease virus,NDV)强毒株感染禽类引起的一种急性、高度接触性传染病。NDV强毒株可导致感染禽类出现呼吸困难、下痢、神经机能紊乱及粘膜、浆膜出血和坏死等典型特征,病死率可达100%,给养禽业造成严重经济损失。世界动物卫生组织(OIE)将新城疫列为法定通报动物疫病,我国农业农村部将其列为一类动物疫病,并在《国家中长期动物疫病防治规划(2012—2020年)》中,将其列为优先防治的重大动物疫病。
NDV为单股、负链、不分节段的RNA病毒,宿主范围广泛,其中以鸡只最易感。NDV具有遗传多样性。根据病毒F基因进行遗传进化分析,NDV可分为I类(class I)和II类(classII)两种类型,其中I类只有1个基因型,II类至少有21个基因型(I—XXI)。1984年,我国台湾地区首次发现基因VII型NDV。随后,该基因型毒株在我国家禽中广泛流行,主要为基因VII.1.1亚型。2011年,我国在广西野鸟中首次分离到基因VII.2亚型NDV。国家新城疫参考实验室监测数据显示,2012—2018年我国陆续在家禽中也分离到VII.2亚型毒株,并可能成为优势基因型。
疫苗免疫是预防新城疫的重要手段,目前广泛使用的新城疫疫苗主要有II系苗B1、IV系苗LaSota、clone30、V4活疫苗以及A-VII油乳剂灭活苗和LaSota油乳剂灭活苗等,这些疫苗虽然可以提供一定的免疫保护,但是不能完全阻止新城疫病毒的扩散、传播,特别是基因VII型新城疫病毒在我国的流行给养殖业造成巨大损失。目前养殖场免疫的基因VII型新城疫疫苗是针对基因VII.1.1亚型研制的,其对现流行的基因VII.2亚型毒株存在免疫失败的风险。鉴于此,为促进我国养禽业健康发展,最终达到新城疫净化的目标,研制基因VII.2亚型NDV疫苗具有重要的意义。
发明内容
本发明的目的在于提供一种HN蛋白突变的基因VII型新城疫病毒重组疫苗株及其构建方法和应用,所构建的疫苗株的毒力高度减弱,在鸡胚上具有较高繁殖能力,免疫原性好,能够用于防控目前流行的基因VII.2亚型NDV。
本发明首先提供一种用于构建基因VII型新城疫病毒重组疫苗株的基因片段,是用包含了毒性致弱的基因VII.2亚型NDV的囊膜糖蛋白F蛋白基因片段和HN蛋白基因片段替换LaSota株基因组的对应部分的基因片段;
所述的毒性致弱的基因VII.2亚型NDV的囊膜糖蛋白F蛋白基因,是将氨基酸序列为SEQ ID NO:1(一种具体的编码基因的序列为SEQ ID NO:5)的F基因的位点112R-R-R-K-R-F117突变为112G-R-Q-G-R-L117;
所述的HN蛋白基因,其氨基酸序列为SEQ ID NO:2(一种具体的编码基因的序列为SEQ ID NO:6);
更进一步的,是将HN蛋白的长度从571aa延长至577aa,其氨基酸序列为SEQ IDNO:3(一种具体的编码基因的序列为SEQ ID NO:7);
作为实施例的具体记载,所述的含了毒性致弱的基因VII.2亚型NDV的囊膜糖蛋白F蛋白基因和HN蛋白基因的,用于构建基因VII型新城疫病毒重组疫苗株的基因片段的一种具体核苷酸序列为SEQ ID NO:4;
本发明还提供了一种基因VII型新城疫病毒重组疫苗株,是使用上述的基因片段构建的,其构建方法包括以下步骤:
1)构建包含基因II型新城疫病毒LaSota株基因组全长cDNA质粒;
2)在1)中构建的LaSota株基因组全长cDNA质粒上,用进行了毒性致弱的基因VII.2亚型NDV的囊膜糖蛋白F蛋白基因和HN蛋白基因片段替换LaSota株基因组的对应部分片段获得全长重组质粒;
3)将2)中构建的全长重组质粒与表达新城疫病毒LaSota毒株NP、P和L基因的真核表达质粒共转染表达T7聚合酶的细胞,获得表达基因VII型F和HN蛋白的重组新城疫病毒弱毒疫苗株;
所述的细胞为BSR-T7/5细胞。
本发明的再一个目的是提供所述的HN蛋白突变的基因VII型新城疫病毒重组疫苗株在制备疫苗中的应用;
所述的疫苗为灭活疫苗,是通过甲醛对弱毒株进行灭活。
本发明提供的HN蛋白突变的基因VII型新城疫病毒重组疫苗株是将进行了致弱突变的基因VII型新城疫病毒的囊膜糖蛋白F蛋白基因和HN蛋白基因片段与LaSota株基因组的对应部分基因进行替换,拯救获得了基因VII型新城疫病毒重组致弱疫苗株。该重组弱毒株遗传稳定,并具有高生长滴度和低致病力的生物学特性。该重组弱毒株制备的疫苗能诱导产生较高的中和抗体,并能有效抑制排毒,能够用于防控强毒力基因VII型以及新流行的基因VII.2亚型NDV的侵害,具有广阔的应用前景。
附图说明
图1为pOK-rLaSota全长质粒构建示意图,图中倒三角形状所示为有别于野生型毒株序列而引入的分子标记(突变的单一酶切位点);
图2为拯救病毒rLaSota株全长cDNA的突变位置的测序结果图;
图3为全长基因组质粒pOK-rLa-VII-YN17和pOK-rLa-VII-571-YN17构建示意图;
图4为基因VII型NDV重组疫苗候选株rLa-VII-YN17和rLa-VII-571-YN17第1代、第5代、第10代、第15代与NDV YN1106/2017株F基因裂解位点测序比对结果。
具体实施方式
本发明设计了一种表达基因VII型NDV F和HN基因重组弱毒疫苗rLa-VII-YN17的构建方法,在建立基因II型新城疫病毒LaSota株的反向遗传操作平台基础上,将中国主要流行的新城疫病毒基因VII.2亚型分离株YN1106/2017的囊膜糖蛋白F蛋白基因和HN蛋白基因片段与LaSota株基因组的对应部分基因进行替换,同时将F蛋白的强毒裂解位点(112R-R-R-K-R-F117)突变为弱毒株LaSota的F蛋白裂解位点(112G-R-Q-G-R-L117),并将HN蛋白的长度从571aa延长至577aa,构建出致弱的表达NDV基因VII.2亚型F和HN基因的全长cDNA克隆质粒pOK-rLa-VII-YN17,与辅助质粒共转染BSR-T7/5细胞后拯救出重组NDV弱毒疫苗株rLa-VII-YN17。
本发明还提供了一种所述的HN蛋白突变的基因VII型新城疫病毒重组疫苗株rLa-VII-YN17的构建方法,包括如下步骤:
(1)构建基因II型新城疫病毒LaSota株基因组全长cDNA质粒pOK-rLaSota;
(2)构建重组质粒pOK-rLa-VII-YN17,在pOK-rLaSota基础上,用Bgl II和HindIII限制性内切酶切割B片段与C片段,结合同源重组的方法,将基因VII.2亚型新城疫病毒YN1106/2017株的F基因和HN基因片段与LaSota株基因组的对应部分基因进行替换,同时将F蛋白的强毒裂解位点(112R-R-R-K-R-F117)突变为弱毒株LaSota的F蛋白裂解位点(112G-R-Q-G-R-L117),并将HN蛋白的长度从571aa延长至577aa,获得重组质粒pOK-rLa-VII-YN17;
(3)重组致弱毒株rLa-VII-YN17的拯救,将全长质粒pOK-rLa-VII-YN17与表达NDVLaSota毒株NP、P和L基因的pCI-NP、pCI-P和pCI-L三个真核表达质粒共转染表达T7聚合酶的BSR-T7/5细胞,转染6h后添加TPCK胰酶,孵育72h,将转染样品反复冻融后接种9~11日龄SPF鸡胚,即获得表达基因VII型F和HN蛋白的重组新城疫病毒弱毒疫苗株rLa-VII-YN17。
上述方法中,步骤(1)的pOK-rLaSota通过以下方法构建得到:根据LaSota株的全长cDNA序列特点,将全长基因组分为a、b、c、d、e共5个片段。根据克隆需要设计引物对部分片段进行相应的突变修饰,以保证克隆所使用的酶切位点的单一性,突变的碱基序列可以作为拯救病毒的分子标签,并在a片段的5’上游引入T7启动子序列,在T7启动子的后面引入三个连续的G碱基来加强其转录活性,在e片段的3’端引入丁肝核酶(HdvRz)序列和T7终止子序列。随后将各个片段依次克隆到pOK12载体中。在实施例中构建完成基因组全长质粒命名为pOK-rLaSota。
本发明的再一个目的是提供所述的新城疫病毒重组疫苗株rLa-VII-YN17的应用。
含有上述表达基因VII型新城疫病毒F和延长的HN蛋白基因重组弱毒疫苗株rLa-VII-YN17的生物制品属于本发明的保护范围。
对重组疫苗株rLa-VII-YN17遗传稳定性进行分析,结果表明rrLa-VII-YN17株在9~11日龄SPF鸡胚中连续传代至第15代,其第1代(F1)、第5代(F5)和第10代(F10)和第15代(F15)病毒经序列测定均含有基因VII型新城疫病毒的F(突变裂解位点)和HN序列,并含有构建时引入的分子标签,病毒遗传稳定性好。
本发明设计的基因VII型新城疫病毒重组疫苗株rLa-VII-YN17,是将基因VII.2亚型新城疫病毒F蛋白的强毒裂解位点112R-R-R-K-R-F117突变为弱毒株LaSota的F蛋白裂解位点112G-R-Q-G-R-L117,并将HN蛋白的长度从571aa延长至577aa,该突变后序列能够使其毒力降低,毒株的安全性更好。
本发明设计的基因VII型新城疫病毒重组疫苗株rLa-VII-YN17使用新城疫病毒基因II型经典疫苗株LaSota株的NP、P、M和L基因作为骨架,其保留了LaSota毒株高繁殖滴度的特性,该重组疫苗株在鸡胚上表现出了优异的生长特性。
所述的疫苗为灭活疫苗,是通过甲醛对弱毒株进行灭活。
免疫保护实验结果表明,重组疫苗株rLa-VII-YN17制备的灭活疫苗对鸡只安全且无副反应;免疫28日龄SPF鸡2周后可产生较高水平抗体,3周后抗体水平更高;免疫3周后用基因VII型新城疫病毒强毒野毒株YN1106/2017进行攻毒,免疫组鸡只未出现任何发病症状或者死亡,免疫保护率达到100%,并可有效抑制排毒,而对照组的死亡率以及拭子病毒排毒检出率均为100%。
下面结合具体实施例对本发明做进一步的说明。
实施例中的实验方法,若未特别指明,均为本领域技术人员所熟知的常规手段,所用原料均为市售商品。实施例中所用的试验材料,如无特殊说明,均为常规生化试剂公司购买得到的。
实施例1:LaSota株的拯救
1、病毒纯化
病毒的纯化是为了获得单一的病毒克隆,采用有限稀释法对LaSota株进行了纯化,详细步骤如下:对病毒液进行10倍倍比稀释,稀释后分别取各滴度病毒液接种9~11日龄SPF鸡胚(100μL/枚),每个稀释度接种5枚。4d后收获鸡胚尿囊液测定HA活性。选取具有HA活性的最高稀释倍数的尿囊液作为下一代纯化的病毒液。用同样的方法进行倍比稀释和鸡胚接种,对病毒连续纯化5代,分装保存第5代病毒液,将其作为原始种毒用于下一步试验。
2、病毒序列测定
以纯化后的病毒反转录基因组cDNA为模板,利用设计的扩增LaSota株全长序列的13对引物(表1),对LaSota基因组进行PCR扩增,同时使用3′-RACE和5′-RACE试剂盒测定了病毒基因组两个末端序列。通过DNA Star生物学软件对所测得的序列进行拼接。结果表明,NDV LaSota株基因组全长为15186bp。
表1:LaSota株NDV全基因组测序用引物表
Figure BDA0003294242230000081
Figure BDA0003294242230000091
3、LaSota全长cDNA克隆质粒的构建
根据LaSota基因组的序列特点,通过酶切位点的筛选,将全长基因组分为5个片段(片段a-e)。设计引物扩增这5个片段(表2),并对P基因、M基因和L基因上的三个酶切位点进行突变,以保证Bgl II和Hind III酶切位点的单一性,突变的碱基序列可以作为拯救病毒的分子标签。在a片段的5’上游引入T7启动子序列,在T7启动子的后面引入三个连续的G碱基来加强其转录活性,在e片段的3’端引入丁肝核酶(HdvRz)序列和T7终止子序列。随后将各个片段依次连接到pOK12克隆载体中,构建策略如图1。在完成全长基因组克隆后进行序列测定,将构建完成且测序正确的病毒基因组质粒命名为pOK-rLaSota。
表2:LaSota毒株基因组全长cDNA克隆构建所用引物表
Figure BDA0003294242230000101
4、辅助质粒的构建
根据测定的LaSota株基因组序列,设计引物分别扩增其编码核衣壳蛋白NP、磷蛋白P和聚合酶蛋白L的开放阅读框(表3),并将3个ORF分别克隆至真核表达载体pCI-neo的CMA启动子下游,构建3个辅助质粒pCI-NP、pCI-P和pCI-L,经测序验证无基因突变产生。
表3:LaSota辅助质粒构建所用引物表
Figure BDA0003294242230000111
5、病毒的拯救
将已构建好的全长质粒(pOK-rLaSota)和3个辅助质粒(pCI-NP、pCI-P和pCI-L)共同转染BSR-T7/5细胞。转染6h后,更换成含2%血清、1%抗生素、5μg/mL的TPCK-Trypsin的DMEM培养基。转染72h后收获培养液及细胞,接种9~11日龄SPF鸡胚(200μL/枚),37℃孵育,3~4d后收获鸡胚尿囊液,并进行血凝(HA)试验。结果显示为HA阳性,初步表明病毒拯救成功。
6、拯救病毒rLaSota的鉴定及生物学特性分析
提取HA阳性的病毒液RNA,对拯救病毒进行全基因组序列测定。序列比对结果显示拯救病毒基因组中含有构建时引入的分子标签(突变的酶切位点,图2),表明LaSota株基因组cDNA克隆成功拯救,将拯救的病毒命名为rLaSota。将其继续在9~11日龄SPF鸡胚中连续传至5代。检测每代的血凝效价其可达210~211之间。对F5代病毒液进行序列测定,结果显示,分子标签未发生回复突变,表明拯救的rLaSota具有较好的稳定性。测定拯救病毒与亲本毒的鸡胚半数感染量(EID50)、鸡胚平均致死时间(MDT)和1日龄雏鸡脑内接种致病指数(ICPI),表4显示了拯救病毒与亲本病毒具有相同的生物学特性和致病性。
表4:拯救病毒与亲本毒株的生物学特性表
Figure BDA0003294242230000121
综上所述,本发明的新城疫病毒LaSota株的反向遗传操作平台构建成功,其可作为良好的疫苗载体使用。
实施例2:重组新城疫疫苗候选种毒的拯救
1、病毒的筛选及纯化
选取实验室分离保存的当前中国主要流行的基因VII.2亚型鸡源新城疫病毒进行繁殖复壮,进而采用有限稀释法对5株毒株进行纯化,各毒株不同代次的血凝效价见表5。最终选取纯化5代后的YN1106/2017毒株,作为原始种毒用于全长cDNA克隆的构建。
表5:基因VII型新城疫病毒不同毒株各代次血凝效价表
Figure BDA0003294242230000131
2、YN1106/2017株全长基因组序列的测定和分析
以纯化后的YN1106/2017病毒反转录基因组cDNA为模板,利用设计的扩增VII型NDV全长序列的12对引物(表6),对YN1106/2017基因组进行PCR扩增,同时使用3’RACE和5’RACE试剂盒测定了病毒基因组两个末端序列。通过DNA Star生物学软件对所测得的序列进行拼接。结果表明,YN1106/2017株基因组全长为15192bp。
表6:VII型NDV全基因组测序用引物表
Figure BDA0003294242230000132
Figure BDA0003294242230000141
3、疫苗候选株基因组全长cDNA构建
以pOK-LaSota全长质粒为平台,设计合成该全长序列中从Bgl II酶切位点到HindIII酶切位点中间的新基因序列YN17-571HN-bc,共6539bp,其包含将基因VII型新城疫病毒YN1106/2017株的囊膜糖蛋白F蛋白基因和HN蛋白基因片段与LaSota株基因组的对应部分基因进行替换,同时将F蛋白(SEQ ID NO:1)的强毒裂解位点(112R-R-R-K-R-F117)突变为弱毒株LaSota的F蛋白裂解位(112G-R-Q-G-R-L117),其他序列保持不变,设计重组病毒rLa-VII-571-YN17株。
在上述突变基础上,并同时设计合成包含将HN蛋白的长度从571aa(SEQ ID NO:2)延长至577aa(SEQ ID NO:3)的另一个新基因序列YN17-577HN-bc(SEQ ID NO:4),共6539bp,设计重组病毒rLa-VII-YN17株。
使用Bgl II和Hind III两个限制性内切酶对pOK-rLaSota全长质粒进行双酶切,剪切掉原来的b、c两个片段。设计引物扩增合成的目的基因YN17-571HN-bc和YN17-577HN-bc片段(表7),将胶回收的目的片段YN17-571HN-bc和YN17-577HN-bc片段分别与酶切后的载体进行连接,构建策略如图3。在完成全长基因组克隆后进行序列测定,将构建完成且测序正确的病毒基因组质粒分别命名为pOK-rLa-VII-571-YN17和pOK-rLa-VII-YN17。
表7:用于扩增YN17-571HN-bc和YN17-577HN-bc片段的引物表
Figure BDA0003294242230000151
Figure BDA0003294242230000161
4、疫苗候选株的拯救
将已构建好的两个全长重组质粒(pOK-rLa-VII-571-YN17和pOK-rLa-VII-YN17)分别和LaSota病毒的3个辅助质粒(pCI-NP、pCI-P和pCI-L)共同转染BSR-T7/5细胞。转染6h后,更换成含2%血清、1%抗生素、5μg/mL的TPCK-Trypsin的DMEM培养基。转染后72h收获培养液及细胞,接种9~11日龄SPF鸡胚(200μL/枚),37℃孵育,3~4d后收获鸡胚尿囊液,并进行血凝(HA)试验。结果都显示为HA阳性,初步表明病毒拯救成功。
5、疫苗候选株的序列鉴定和遗传稳定性
选取HA阳性的病毒液提取RNA并进行反转录后,进行全基因组序列测定。序列比对结果显示拯救病毒rLa-VII-571-YN17基因组为以LaSota株为骨架,嵌合YN1106/2017株的F和HN基因,并且F基因裂解位点已突变;拯救病毒rLa-VII-YN17基因组为以LaSota株为骨架,嵌合YN1106/2017株的F和HN基因,并且F基因裂解位点已突变,HN蛋白的长度从571aa延长至577aa,表明两株病毒均获得成功拯救。
将拯救病毒继续在9~11日龄SPF鸡胚中连续传代15次。每代病毒的血凝效价均在210~211之间。选取第1代、第5代、第10代和第15代重组病毒的F和HN基因进行序列测定。测序结果表明,第1代、第5代、第10代和第15代重组病毒的F和HN基因均与***的序列一致,F蛋白裂解位点也未发生回复突变(图4),表明两株重组病毒传代过程中遗传稳定。
6、疫苗候选株的生物学特性
选取第15代rLa-VII-YN17和rLa-VII-571-YN17疫苗候选株测定其EID50、MDT和ICPI,并以病毒Lasota株和YN1106/2017株作为对照,比较病毒的毒力变化情况。表8的试验数据表明,本发明拯救的rLa-VII-YN17和rLa-VII-571-YN17疫苗候选株毒力都明显降低,而具有HN蛋白长度延长的rLa-VII-YN17疫苗候选株相较于rLa-VII-571-YN17疫苗候选株在鸡胚中具有更高生长滴度以及对1日龄雏鸡有更低致病力的生物学特性。因此,本发明构建的rLa-VII-YN17疫苗候选株可作为优选疫苗株用于疫苗生产。
表8:拯救病毒与亲本毒株的生物学特性表
Figure BDA0003294242230000171
实施例3 rLa-VII-YN17疫苗株对SPF鸡安全性试验和免疫效果试验
1、灭活疫苗的制备
rLa-VII-YN17疫苗株用灭菌生理盐水稀释10 000倍,接种9~11日龄SPF鸡胚,每胚接0.1mL,置37℃继续孵育。将接种后24h内死胚弃去,24h~120h死胚及时放4℃,收混合样,测定制苗毒的HA为28,病毒滴度为109.65EID50/0.1mL。将测定好效价的新城疫病毒液导入灭活罐内,加入终浓度为0.1%的甲醛溶液使其充分混合,4℃灭活48h,期间每隔2h摇晃一次。灭活后的病毒原液按常规方法制备油佐剂灭活疫苗。
2、灭活疫苗的超剂量接种安全性试验
为测定本发明实施例2拯救的rLa-VII-YN17疫苗株对SPF鸡的安全性,将制备的rLa-VII-YN17灭活疫苗免疫7日龄SPF鸡16只,每只肌肉注射疫苗1.0mL,同时设对照5只,在相同的条件下饲养,连续观察14日,记录试验鸡只采食、饮水及临床情况。免疫后3天和7天每组剖检3只鸡,观察肝脏、脾脏、胰腺、十二指肠、腺胃、气管、盲肠扁桃体、法氏囊、心脏、脑、肺脏、肾脏和胸腺等组织脏器是否出现病变。结果显示,鸡只免疫后疫苗吸收效果良好,饮食、饮水、排便正常,均未表现出任何局部和全身的不良反应,剖检鸡只各脏器均无病变。
3、灭活疫苗的免疫效果评价
为测定本发明实施例2拯救的rLa-VII-YN17疫苗株对SPF鸡的免疫保护效果,将饲养于隔离器内的28日龄的SPF鸡20只,随机分成两组,每组10只,一组为实施例3步骤1所制备的rLa-VII-YN17灭活疫苗免疫组,一组为阴性对照组。免疫组每只鸡肌肉注射疫苗20μL,对照组注射相同剂量的PBS。分别于免疫后7天、14天和21天采血,分离血清,测定抗体。21天采血后,用临床分离的基因VII型野毒株强毒YN1106/2017株攻毒,每只鸡以106EID50剂量经肌肉注射途径进行攻毒,隔离器饲养,观察14天,每天记录鸡只发病和死亡情况;攻毒后3天、5天、7天和10天采集两组鸡口咽拭子和泄殖腔拭子口咽拭子和泄殖腔拭子接种鸡胚进行病毒分离,检测排毒情况。
结果显示,免疫组免疫14天后可产生较高水平抗体,21天抗体水平更高,结果见表9。攻毒后,在14天的观察期内,免疫组未出现任何发病或死亡,免疫保护率达到100%;而对照组鸡只则在攻毒3~4后全部死亡,结果见表10。表11的排毒结果显示,rLa-VII-YN17灭活疫苗免疫组仅在攻毒后第5天有一只鸡排毒,阴性对照组排毒率为100%。
表9:免疫后抗体效价测定表
Figure BDA0003294242230000191
Figure BDA0003294242230000201
表10:免疫效力试验结果表
Figure BDA0003294242230000202
表11:攻毒后试验鸡排毒检测结果表
Figure BDA0003294242230000203
综上所述,本发明所制备的灭活的基因VII型新城疫病毒重组疫苗株rLa-VII-YN17,对免疫鸡只具有较好的安全性和保护效果,具有广阔的应用前景。
上述内容仅为本发明创造的优选实施例,不能以此限定本发明创造的实施范围,即凡是未脱离本发明技术方案的内容,依本发明创造权利要求及发明创造说明内容对以上实施例所做出的简单变化、等效变化与修饰,均仍属于本发明技术方案涵盖的范围。
序列表
<110> 中国动物卫生与流行病学中心
<120> 一种HN蛋白突变的基因VII型新城疫病毒重组疫苗株
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 553
<212> PRT
<213> 新城疫病毒(Newcastle disease virus)
<400> 1
Met Gly Ser Asn Ser Ser Thr Arg Thr Pro Thr Pro Pro Met Leu Val
1 5 10 15
Thr Leu Ile Ile Leu Ile Leu Ser Phe Ile Cys Leu Ala Ser Ser Leu
20 25 30
Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys
35 40 45
Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys
50 55 60
Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Arg Ala Pro
65 70 75 80
Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly
85 90 95
Asp Ser Ile Arg Lys Ile Gln Gly Ser Ala Ser Thr Ser Gly Gly Arg
100 105 110
Arg Arg Lys Arg Phe Ile Gly Ala Ile Ile Gly Ser Val Ala Leu Gly
115 120 125
Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ala Ala Leu Ile Gln Ala
130 135 140
Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala
145 150 155 160
Thr Asn Glu Ala Val His Glu Val Thr Asn Gly Leu Ser Gln Leu Ser
165 170 175
Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Asn
180 185 190
Thr Ala Arg Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val
195 200 205
Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln
210 215 220
Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn
225 230 235 240
Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly
245 250 255
Asn Asn Gln Leu Ser Ser Leu Ile Gly Ser Gly Leu Ile Thr Gly Tyr
260 265 270
Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Asn
275 280 285
Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu
290 295 300
Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro
305 310 315 320
Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser
325 330 335
Tyr Cys Ile Glu Ser Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr
340 345 350
Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser
355 360 365
Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met
370 375 380
Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Ile Thr Thr Cys Arg
385 390 395 400
Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val
405 410 415
Ser Leu Ile Asp Arg Arg Ser Cys Asn Val Leu Ser Leu Asp Gly Ile
420 425 430
Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile
435 440 445
Ser Ile Leu Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser
450 455 460
Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys
465 470 475 480
Leu Ala Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr
485 490 495
Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Val Ile Ser Leu
500 505 510
Val Ser Gly Ala Leu Ser Leu Ile Leu Thr Cys Tyr Leu Met Tyr Lys
515 520 525
Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu
530 535 540
Asp Gln Met Arg Ala Thr Thr Arg Ala
545 550
<210> 2
<211> 571
<212> PRT
<213> 新城疫病毒(Newcastle disease virus)
<400> 2
Met Asp Arg Val Val Asn Arg Val Val Leu Glu Asn Glu Arg Arg Glu
1 5 10 15
Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Thr Val Leu Leu Leu
20 25 30
Leu Ala Met Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala His Ser Met
35 40 45
Arg Ala Cys Thr Leu Arg Asp Leu Ala Gly Ile Ser Thr Gly Ile Ser
50 55 60
Lys Thr Glu Asp Arg Ile Thr Ser Leu Leu Ser Leu Ser Gln Asp Val
65 70 75 80
Ile Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
85 90 95
Leu Asn Thr Glu Ser Ile Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
100 105 110
Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Val His
115 120 125
Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp
130 135 140
Thr Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Tyr Gln Glu His Leu
145 150 155 160
Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro
165 170 175
Ser Phe Asp Met Ser Thr Thr His Tyr Cys Tyr Thr His Asn Val Ile
180 185 190
Phe Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu
195 200 205
Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Ile Phe Phe Ser Thr Leu
210 215 220
Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val
225 230 235 240
Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu
245 250 255
Thr Glu Glu Glu Asp Tyr Arg Ser Val Thr Pro Thr Ser Met Val His
260 265 270
Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Thr
275 280 285
Thr Val Leu Phe Lys Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly
290 295 300
Gly Ser Phe Ile Asn Asp Arg Val Trp Phe Pro Val Tyr Gly Gly Leu
305 310 315 320
Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile
325 330 335
Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile
340 345 350
Arg Met Ala Lys Ser Ser Tyr Lys Pro Gln Arg Phe Gly Gly Lys Arg
355 360 365
Val Gln Gln Ala Ile Leu Ser Ile Glu Val Ser Thr Ser Leu Gly Lys
370 375 380
Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala
385 390 395 400
Glu Gly Arg Ile Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg
405 410 415
Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Ile Val His
420 425 430
Asn Lys Thr Ala Thr Leu His Asn Pro Tyr Thr Phe Asn Ala Phe Thr
435 440 445
Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser
450 455 460
Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Ile Phe His Arg
465 470 475 480
Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Gly Gln
485 490 495
Ala Arg Leu Asn Pro Thr Ser Ala Val Phe Asp Asn Ile Ser Arg Ser
500 505 510
Arg Val Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr
515 520 525
Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser
530 535 540
Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
545 550 555 560
Leu Leu Ile Glu Ile Leu Lys Asp Asp Arg Val
565 570
<210> 3
<211> 577
<212> PRT
<213> 新城疫病毒(Newcastle disease virus)
<400> 3
Met Asp Arg Val Val Asn Arg Val Val Leu Glu Asn Glu Arg Arg Glu
1 5 10 15
Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Thr Val Leu Leu Leu
20 25 30
Leu Ala Met Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala His Ser Met
35 40 45
Arg Ala Cys Thr Leu Arg Asp Leu Ala Gly Ile Ser Thr Gly Ile Ser
50 55 60
Lys Thr Glu Asp Arg Ile Thr Ser Leu Leu Ser Leu Ser Gln Asp Val
65 70 75 80
Ile Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
85 90 95
Leu Asn Thr Glu Ser Ile Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
100 105 110
Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Val His
115 120 125
Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp
130 135 140
Thr Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Tyr Gln Glu His Leu
145 150 155 160
Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro
165 170 175
Ser Phe Asp Met Ser Thr Thr His Tyr Cys Tyr Thr His Asn Val Ile
180 185 190
Phe Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu
195 200 205
Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Ile Phe Phe Ser Thr Leu
210 215 220
Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val
225 230 235 240
Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu
245 250 255
Thr Glu Glu Glu Asp Tyr Arg Ser Val Thr Pro Thr Ser Met Val His
260 265 270
Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Thr
275 280 285
Thr Val Leu Phe Lys Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly
290 295 300
Gly Ser Phe Ile Asn Asp Arg Val Trp Phe Pro Val Tyr Gly Gly Leu
305 310 315 320
Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile
325 330 335
Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile
340 345 350
Arg Met Ala Lys Ser Ser Tyr Lys Pro Gln Arg Phe Gly Gly Lys Arg
355 360 365
Val Gln Gln Ala Ile Leu Ser Ile Glu Val Ser Thr Ser Leu Gly Lys
370 375 380
Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala
385 390 395 400
Glu Gly Arg Ile Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg
405 410 415
Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Ile Val His
420 425 430
Asn Lys Thr Ala Thr Leu His Asn Pro Tyr Thr Phe Asn Ala Phe Thr
435 440 445
Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser
450 455 460
Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Ile Phe His Arg
465 470 475 480
Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Gly Gln
485 490 495
Ala Arg Leu Asn Pro Thr Ser Ala Val Phe Asp Asn Ile Ser Arg Ser
500 505 510
Arg Val Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr
515 520 525
Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser
530 535 540
Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
545 550 555 560
Leu Leu Ile Glu Ile Leu Lys Asp Asp Arg Val Arg Glu Ala Arg Ser
565 570 575
Gly
<210> 4
<211> 6539
<212> DNA
<213> 新城疫病毒(Newcastle disease virus)
<400> 4
agatcttgtc ttgaaacaga catcctccat ccctatgatg cggaccgaaa tccaacagct 60
gaaaacatct gttgcagtca tggaagccaa cttgggaatg atgaagattc tggatcccgg 120
ttgtgccaac atttcatctc tgagtgatct acgggcagtt gcccgatctc acccggtttt 180
agtttcaggc cctggagacc cctctcccta tgtgacacaa ggaggcgaaa tggcacttaa 240
taaactttcg caaccagtgc cacatccatc tgaattgatt aaacccgcca ctgcatgcgg 300
gcctgatata ggagtggaaa aggacactgt ccgtgcattg atcatgtcac gcccaatgca 360
cccgagttct tcagccaagc tcctaagcaa gttagatgca gccgggtcga tcgaggaaat 420
caggaaaatc aagcgccttg ctctaaatgg ttaattacta ctgccacacg tagcgggtcc 480
ctgtccactc ggcatcacac ggaatctgca ccgagttccc ccccgcagac ccaaggtcca 540
actctccaag cggcaatcct ctctcgcttc ctcagcccca ctgaatgatc gcgtaaccgt 600
aattaatcta gctacattta agattaagaa aaaatacggg tagaattgga gtgccccaat 660
tgtgccaaga tggactcatc taggacaatt gggctgtact ttgattctgc ccattcttct 720
agcaacctgt tagcatttcc gatcgtccta caagacacag gagatgggaa gaagcaaatc 780
gccccgcaat ataggatcca gcgccttgac ttgtggactg atagtaagga ggactcagta 840
ttcatcacca cctatggatt catctttcaa gctgggaatg aagaagccac tgtcggcatg 900
atcgatgata aacccaagcg cgagttactt tccgctgcga tgctctgcct aggaagcgtc 960
ccaaataccg gagaccttat tgagctggca agggcctgtc tcactatgat agtcacatgc 1020
aagaagagtg caactaatac tgagagaatg gttttctcag tagtgcaggc accccaagtg 1080
ctgcaaagct gtagggttgt ggcaaacaaa tactcatcag tgaatgcagt caagcacgtg 1140
aaagcgccag agaagattcc cgggagtgga accctagaat acaaggtgaa ctttgtctcc 1200
ttgactgtgg taccgaagaa ggatgtctac aagatcccag ctgcagtatt gaaggtttct 1260
ggctcgagtc tgtacaatct tgcgctcaat gtcactatta atgtggaggt agacccgagg 1320
agtcctttgg ttaaatctct gtctaagtct gacagcggat actatgctaa cctcttcttg 1380
catattggac ttatgaccac cgtagatagg aaggggaaga aagtgacatt tgacaagctg 1440
gaaaagaaaa taaggagcct tgatctatct gtcgggctca gtgatgtgct cgggccttcc 1500
gtgttggtaa aagcaagagg tgcacggact aagctcttgg cacctttctt ctctagcagt 1560
gggacagcct gctatcccat agcaaatgct tctcctcagg tggccaagat actctggagt 1620
caaaccgcgt gcctgcggag cgttaaaatc attatccaag caggtaccca acgcgctatc 1680
gcagtgaccg ccgaccacga ggttacctct actaagctgg agaaggggca cacccttgcc 1740
aaatacaatc cttttaagaa ataagctgcg tctctgagat tgcgctccgc ccactcaccc 1800
agatcatcat gacacaaaaa actaatctgt cttgattatt tacagttagt ttacctgtct 1860
atcaagttag aaaaaacacg ggtagaagat tctggatccc ggttggcgcc ctccaggtgc 1920
aagatgggtt ccaactcttc taccaggacc ccaacacccc cgatgctggt cactctgatc 1980
atactgatat taagcttcat ctgcctggca agctctctcg atggcaggcc tcttgcggct 2040
gcagggattg tggtaacagg agacaaggca gtcaatatct acacctcgtc tcaaacaggg 2100
tcaatcatag tcaagttgct cccgaatatg cccaaagata aagaggcgtg tgcaagagcc 2160
ccattagaag catataatag aacattgact acattgctca ctccccttgg cgattccatc 2220
cgtaagatcc aagggtccgc gtccacgtca ggaggaggga gacaggggcg ccttataggt 2280
gccattattg gcagtgtcgc tcttggagtt gcaacagcgg cacagataac tgcagctgcg 2340
gccctaatac aagccaacca gaatgccgcc aacatcctcc ggcttaagga gagcattgct 2400
gcgaccaatg aagctgtgca tgaagtcacc aacggattat cacaactatc agtggcagtt 2460
ggaaagatgc agcagtttgt caatgaccag tttaataata cggcacgaga attggattgt 2520
ataaaaatta cacaacaggt tggtgtagaa ctcaacctat acctgactga attgactaca 2580
gtattcgggc cacagatcac ttcccctgcc ttaactcagc tgactatcca ggcactttat 2640
aatttagctg ggggcaatat ggattacttg ttaactaagt taggtgtagg gaacaatcaa 2700
ctcagctcat taattggtag cggcttgatt accggatacc ccatactgta tgactcacag 2760
actcaactct tgggtataca agtgaatttg ccctcagtcg gaaacctaaa taatatgcga 2820
gccacctact tggagacctt atctgtgagt acaacaaagg ggtttgcctc agcgcttgtc 2880
cctaaagtag tgacacaagt tggttctgtg atagaagagc ttgacacctc atactgtata 2940
gagtctgatc tggatttata ttgcacaaga atagtgacat tccccatgtc cccaggcatt 3000
tattcttgtt tgagcggcaa cacatcggcc tgcatgtatt caaagactga aggagcactc 3060
actacgccat atatgaccct taaaggctca gttattgcca attgtaagat aacaacatgt 3120
agatgtgcag atcctcctgg tatcatatcg caaaattacg gagaagctgt gtctctgata 3180
gacagacgtt cgtgcaatgt cctatcatta gacgggataa ctctgaggct cagtggggag 3240
tttgatgcaa cttatcaaaa gaatatctca atactagatt ctcaagttat cgtgacaggc 3300
aatctcgata tatcaactga gcttggaaat gtcaacaatt caatcagtaa tgccctagat 3360
aagctggcgg aaagcaacag caagctagat aaagtcaatg tcaaactaac cagcacatca 3420
gctctcatta cttatatcgt tttaacagtc atttctcttg tttctggtgc acttagtttg 3480
attttaacat gttacttgat gtacaagcag aaggcacaac agaagacctt actatggctt 3540
gggaataata ctcttgatca gatgagagcc accacaagag catgaacaca gatgaggaac 3600
gaaggtttcc ctaatagtaa tttatgtgaa agttctggta gtctgtcagt tcagagagtt 3660
aagaaaaaac taccggttgt agatgaccaa aggacgatat acgggtagaa cggtaagaga 3720
ggccgcccct caattgcgag ccaggcttca caacctccgt tctaccgctt caccgacaac 3780
agtcctcaat catggaccgt gtggtcaata gggtcgtgct ggagaatgag agaagagaag 3840
caaagaatac atggcgcttg gtcttccgta tcacagtctt acttttattg gcaatgactc 3900
tagccatctc tgcagccgcc ctggcgcata gcatgagggc ctgtacgctg cgtgacctcg 3960
caggcatatc gacagggatc tccaagacag aagatagaat tacgtcttta ctcagtttaa 4020
gtcaagatgt gatagatagg atatataagc aggtggctct tgaatctccg ctggcgttac 4080
taaatactga atctataatt atgaatgcaa taacctctct ttcctatcaa atcaacggag 4140
ctgcgaatag tagcggatgt ggggcgcctg ttcatgaccc agattatatc ggggggatag 4200
gcaaagaact catagtagac gatactagtg acgtcacttc gttttatcct tctgcgtatc 4260
aagaacactt gaatttcatt ccagcaccca cgacaggatc cggttgcact cggataccct 4320
catttgacat gagcaccact cattattgtt atactcacaa tgtgatattt tctggttgca 4380
gagaccactc acactcacac caatacctag cacttggcgt gctccggaca tctgcaacag 4440
ggaggatatt cttctctact ctgcgttcca tcaatttaga tgacacccaa aatcggaagt 4500
cctgcagtgt gagtgcaact cctttaggtt gtgatatgct atgctctaaa gtcacagaga 4560
ctgaggaaga agattacagg tcagttaccc ccacatcaat ggtgcacgga aggctagggt 4620
ttgatggtca ataccatgag aaggacttag ataccacagt cttatttaaa gattgggtgg 4680
caaattaccc tggggtggga ggtgggtctt ttattaacga ccgtgtatgg ttcccagttt 4740
atggagggct caaacccaat tcacctagtg acaccgcaca agaagggaaa tatgtaatat 4800
acaagcgcta taatgacaca tgccccgatg aacaagatta ccaaatccgg atggctaaat 4860
cttcatataa gccccagcga tttggtggga agcgcgtaca gcaagccatc ttatctattg 4920
aggtgtcaac atctttgggt aaggatccgg tgctgactat tccacctaat acaattacac 4980
tcatgggggc cgaaggcaga attctcacgg tagggacatc tcacttcctg tatcaacgag 5040
gatcttcata tttctccccc gctttattat accccatgat tgtgcataac aaaacggcta 5100
ctctccataa tccttataca tttaatgcct tcactcggcc gggtagcgtc ccttgccagg 5160
catcagcaag atgccccaac tcatgcatca ccggggttta tactgatcca tacccattaa 5220
tcttccatag gaatcatact ttacgagggg tcttcgggac gatgcttgat gatggacaag 5280
caagacttaa tcccacatct gcagtatttg acaacatatc ccgcagtcgt gtaactcggg 5340
tgagttcaag cagcaccaag gcagcataca caacatcaac atgttttaaa gttgtcaaga 5400
ccaataaaac ttattgtctt agtattgcag aaatatccaa caccctattc ggggaattta 5460
ggattgttcc cttactgatt gagatcctca aggatgatag agtcagagaa gccaggtctg 5520
gctagttgag tcaattataa aggagttgga aagatggcat tgtatcacct atcctctgcg 5580
acatcaagaa tcaaaccgaa tgccggcgcg tgctcgaatt ccatgttgcc agttgaccac 5640
aatcagccag tgctcatgcg atcagattaa gccttgtcaa tagtctcttg atttagaaaa 5700
aatgtaagtg gcaatgagat acaaggcaaa acagctcatg gtaaataata cgggtaggac 5760
atggcgagct ccggtcctga aagggcagag catcagatta tcctaccaga gtcacacctg 5820
tcttcaccat tggtcaagca caaactactc tattactgga aattaactgg gctaccgctt 5880
cctgatgaat gtgacttcga ccacctcatt ctcagccgac aatggaaaaa aatacttgaa 5940
tcggcctctc ctgatactga gagaatgata aaactcggaa gggcagtaca ccaaactctt 6000
aaccacaatt ccagaataac cggagtgctc caccccaggt gtttagaaga actggctaat 6060
attgaggtcc cagattcaac caacaaattt cggaagattg agaagaagat ccaaattcac 6120
aacacgagat atggagaact gttcacaagg ctgtgtacgc atatagagaa gaaactgctg 6180
gggtcatctt ggtctaacaa tgtcccccgg tcagaggagt tcagcagcat tcgtacggat 6240
ccggcattct ggtttcactc aaaatggtcc acagccaagt ttgcatggct ccatataaaa 6300
cagatccaga ggcatctgat ggtggcagct aggacaaggt ctgcggccaa caaattggtg 6360
atgctaaccc ataaggtagg ccaagtcttt gtcactcctg aacttgtcgt tgtgacgcat 6420
acgaatgaga acaagttcac atgtcttacc caggaacttg tattgatgta tgcagatatg 6480
atggagggca gagatatggt caacataata tcaaccacgg cggtgcatct cagaagctt 6539
<210> 5
<211> 1662
<212> DNA
<213> 新城疫病毒(Newcastle disease virus)
<400> 5
atgggttcca actcttctac caggacccca acacccccga tgctggtcac tctgatcata 60
ctgatattaa gcttcatctg cctggcaagc tctctcgatg gcaggcctct tgcggctgca 120
gggattgtgg taacaggaga caaggcagtc aatatctaca cctcgtctca aacagggtca 180
atcatagtca agttgctccc gaatatgccc aaagataaag aggcgtgtgc aagagcccca 240
ttagaagcat ataatagaac attgactaca ttgctcactc cccttggcga ttccatccgt 300
aagatccaag ggtccgcgtc cacgtcagga ggaaggagac ggaaacgctt tataggtgcc 360
attattggca gtgtcgctct tggagttgca acagcggcac agataactgc agctgcggcc 420
ctaatacaag ccaaccagaa tgccgccaac atcctccggc ttaaggagag cattgctgcg 480
accaatgaag ctgtgcatga agtcaccaac ggattatcac aactatcagt ggcagttgga 540
aagatgcagc agtttgtcaa tgaccagttt aataatacgg cacgagaatt ggattgtata 600
aaaattacac aacaggttgg tgtagaactc aacctatacc tgactgaatt gactacagta 660
ttcgggccac agatcacttc ccctgcctta actcagctga ctatccaggc actttataat 720
ttagctgggg gcaatatgga ttacttgtta actaagttag gtgtagggaa caatcaactc 780
agctcattaa ttggtagcgg cttgattacc ggatacccca tactgtatga ctcacagact 840
caactcttgg gtatacaagt gaatttgccc tcagtcggaa acctaaataa tatgcgagcc 900
acctacttgg agaccttatc tgtgagtaca acaaaggggt ttgcctcagc gcttgtccct 960
aaagtagtga cacaagttgg ttctgtgata gaagagcttg acacctcata ctgtatagag 1020
tctgatctgg atttatattg cacaagaata gtgacattcc ccatgtcccc aggcatttat 1080
tcttgtttga gcggcaacac atcggcctgc atgtattcaa agactgaagg agcactcact 1140
acgccatata tgacccttaa aggctcagtt attgccaatt gtaagataac aacatgtaga 1200
tgtgcagatc ctcctggtat catatcgcaa aattacggag aagctgtgtc tctgatagac 1260
agacgttcgt gcaatgtcct atcattagac gggataactc tgaggctcag tggggagttt 1320
gatgcaactt atcaaaagaa tatctcaata ctagattctc aagttatcgt gacaggcaat 1380
ctcgatatat caactgagct tggaaatgtc aacaattcaa tcagtaatgc cctagataag 1440
ctggcggaaa gcaacagcaa gctagataaa gtcaatgtca aactaaccag cacatcagct 1500
ctcattactt atatcgtttt aacagtcatt tctcttgttt ctggtgcact tagtttgatt 1560
ttaacatgtt acttgatgta caagcagaag gcacaacaga agaccttact atggcttggg 1620
aataatactc ttgatcagat gagagccacc acaagagcat ga 1662
<210> 6
<211> 1716
<212> DNA
<213> 新城疫病毒(Newcastle disease virus)
<400> 6
atggaccgtg tggtcaatag ggtcgtgctg gagaatgaga gaagagaagc aaagaataca 60
tggcgcttgg tcttccgtat cacagtctta cttttattgg caatgactct agccatctct 120
gcagccgccc tggcgcatag catgagggcc tgtacgctgc gtgacctcgc aggcatatcg 180
acagggatct ccaagacaga agatagaatt acgtctttac tcagtttaag tcaagatgtg 240
atagatagga tatataagca ggtggctctt gaatctccgc tggcgttact aaatactgaa 300
tctataatta tgaatgcaat aacctctctt tcctatcaaa tcaacggagc tgcgaatagt 360
agcggatgtg gggcgcctgt tcatgaccca gattatatcg gggggatagg caaagaactc 420
atagtagacg atactagtga cgtcacttcg ttttatcctt ctgcgtatca agaacacttg 480
aatttcattc cagcacccac gacaggatcc ggttgcactc ggataccctc atttgacatg 540
agcaccactc attattgtta tactcacaat gtgatatttt ctggttgcag agaccactca 600
cactcacacc aatacctagc acttggcgtg ctccggacat ctgcaacagg gaggatattc 660
ttctctactc tgcgttccat caatttagat gacacccaaa atcggaagtc ctgcagtgtg 720
agtgcaactc ctttaggttg tgatatgcta tgctctaaag tcacagagac tgaggaagaa 780
gattacaggt cagttacccc cacatcaatg gtgcacggaa ggctagggtt tgatggtcaa 840
taccatgaga aggacttaga taccacagtc ttatttaaag attgggtggc aaattaccct 900
ggggtgggag gtgggtcttt tattaacgac cgtgtatggt tcccagttta tggagggctc 960
aaacccaatt cacctagtga caccgcacaa gaagggaaat atgtaatata caagcgctat 1020
aatgacacat gccccgatga acaagattac caaatccgga tggctaaatc ttcatataag 1080
ccccagcgat ttggtgggaa gcgcgtacag caagccatct tatctattga ggtgtcaaca 1140
tctttgggta aggatccggt gctgactatt ccacctaata caattacact catgggggcc 1200
gaaggcagaa ttctcacggt agggacatct cacttcctgt atcaacgagg atcttcatat 1260
ttctcccccg ctttattata ccccatgatt gtgcataaca aaacggctac tctccataat 1320
ccttatacat ttaatgcctt cactcggccg ggtagcgtcc cttgccaggc atcagcaaga 1380
tgccccaact catgcatcac cggggtttat actgatccat acccattaat cttccatagg 1440
aatcatactt tacgaggggt cttcgggacg atgcttgatg atggacaagc aagacttaat 1500
cccacatctg cagtatttga caacatatcc cgcagtcgtg taactcgggt gagttcaagc 1560
agcaccaagg cagcatacac aacatcaaca tgttttaaag ttgtcaagac caataaaact 1620
tattgtctta gtattgcaga aatatccaac accctattcg gggaatttag gattgttccc 1680
ttactgattg agatcctcaa ggatgataga gtctga 1716
<210> 7
<211> 1734
<212> DNA
<213> 新城疫病毒(Newcastle disease virus)
<400> 7
atggaccgtg tggtcaatag ggtcgtgctg gagaatgaga gaagagaagc aaagaataca 60
tggcgcttgg tcttccgtat cacagtctta cttttattgg caatgactct agccatctct 120
gcagccgccc tggcgcatag catgagggcc tgtacgctgc gtgacctcgc aggcatatcg 180
acagggatct ccaagacaga agatagaatt acgtctttac tcagtttaag tcaagatgtg 240
atagatagga tatataagca ggtggctctt gaatctccgc tggcgttact aaatactgaa 300
tctataatta tgaatgcaat aacctctctt tcctatcaaa tcaacggagc tgcgaatagt 360
agcggatgtg gggcgcctgt tcatgaccca gattatatcg gggggatagg caaagaactc 420
atagtagacg atactagtga cgtcacttcg ttttatcctt ctgcgtatca agaacacttg 480
aatttcattc cagcacccac gacaggatcc ggttgcactc ggataccctc atttgacatg 540
agcaccactc attattgtta tactcacaat gtgatatttt ctggttgcag agaccactca 600
cactcacacc aatacctagc acttggcgtg ctccggacat ctgcaacagg gaggatattc 660
ttctctactc tgcgttccat caatttagat gacacccaaa atcggaagtc ctgcagtgtg 720
agtgcaactc ctttaggttg tgatatgcta tgctctaaag tcacagagac tgaggaagaa 780
gattacaggt cagttacccc cacatcaatg gtgcacggaa ggctagggtt tgatggtcaa 840
taccatgaga aggacttaga taccacagtc ttatttaaag attgggtggc aaattaccct 900
ggggtgggag gtgggtcttt tattaacgac cgtgtatggt tcccagttta tggagggctc 960
aaacccaatt cacctagtga caccgcacaa gaagggaaat atgtaatata caagcgctat 1020
aatgacacat gccccgatga acaagattac caaatccgga tggctaaatc ttcatataag 1080
ccccagcgat ttggtgggaa gcgcgtacag caagccatct tatctattga ggtgtcaaca 1140
tctttgggta aggatccggt gctgactatt ccacctaata caattacact catgggggcc 1200
gaaggcagaa ttctcacggt agggacatct cacttcctgt atcaacgagg atcttcatat 1260
ttctcccccg ctttattata ccccatgatt gtgcataaca aaacggctac tctccataat 1320
ccttatacat ttaatgcctt cactcggccg ggtagcgtcc cttgccaggc atcagcaaga 1380
tgccccaact catgcatcac cggggtttat actgatccat acccattaat cttccatagg 1440
aatcatactt tacgaggggt cttcgggacg atgcttgatg atggacaagc aagacttaat 1500
cccacatctg cagtatttga caacatatcc cgcagtcgtg taactcgggt gagttcaagc 1560
agcaccaagg cagcatacac aacatcaaca tgttttaaag ttgtcaagac caataaaact 1620
tattgtctta gtattgcaga aatatccaac accctattcg gggaatttag gattgttccc 1680
ttactgattg agatcctcaa ggatgataga gtcagagaag ccaggtctgg ctag 1734

Claims (6)

1.一种用于构建基因VII型新城疫病毒重组疫苗株的基因片段,其特征在于,所述的基因片段的核苷酸序列为SEQ ID NO:4。
2.权利要求1所述的用于构建基因VII型新城疫病毒重组疫苗株的基因片段在构建基因VII型新城疫病毒重组疫苗株中的应用。
3.一种基因VII型新城疫病毒重组疫苗株,其特征在于,所述的疫苗株是使用权利要求1所述的用于构建基因VII型新城疫病毒重组疫苗株的基因片段,与辅助质粒共转染细胞后遗传拯救的。
4.如权利要求3所述的基因VII型新城疫病毒重组疫苗株,其特征在于,所述的细胞为BSR-T7/5细胞。
5.权利要求3或4所述的基因VII型新城疫病毒重组疫苗株在制备疫苗中的应用。
6.一种灭活疫苗,其特征在于,所述的灭活疫苗,其中抗原包含有灭活的如权利要求3或4所述的基因VII型新城疫病毒重组疫苗株。
CN202111173227.2A 2021-10-08 2021-10-08 一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株 Active CN113897376B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111173227.2A CN113897376B (zh) 2021-10-08 2021-10-08 一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111173227.2A CN113897376B (zh) 2021-10-08 2021-10-08 一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株

Publications (2)

Publication Number Publication Date
CN113897376A CN113897376A (zh) 2022-01-07
CN113897376B true CN113897376B (zh) 2022-05-20

Family

ID=79190500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111173227.2A Active CN113897376B (zh) 2021-10-08 2021-10-08 一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株

Country Status (1)

Country Link
CN (1) CN113897376B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107158369A (zh) * 2017-05-27 2017-09-15 山东信得科技股份有限公司 一种使用构建的基因vii型新城疫病毒弱毒株制备的疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107158369A (zh) * 2017-05-27 2017-09-15 山东信得科技股份有限公司 一种使用构建的基因vii型新城疫病毒弱毒株制备的疫苗

Also Published As

Publication number Publication date
CN113897376A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
CN107815441B (zh) 一种ⅱ型伪狂犬病毒减毒株及其制备方法和应用
CN113736800B (zh) 一种鸽源新城疫病毒重组疫苗株及其构建方法和应用
CN111019910B (zh) F基因型腮腺炎病毒减毒株及构建方法和应用
CN104962581B (zh) 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株
CN114107228B (zh) 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
CN113862230A (zh) 一种猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
CN114164184B (zh) 一种新城疫病毒基因ⅵ型疫苗株及其应用
CN109321535A (zh) 一种热稳定的新城疫病毒弱毒疫苗候选株
CN109321534A (zh) 一种重组基因viii型新城疫病毒弱毒株
CN117417904A (zh) 表达C型aMPV F蛋白和G蛋白的新城疫病毒载体疫苗株及其应用
CN106520710A (zh) 表达鸭坦布苏病毒prm和E蛋白重组新城疫病毒活载体疫苗的制备及应用
US11744888B2 (en) Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein
CN114015660B (zh) 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
CN112852758B (zh) 一种表达鸡传染性支气管炎病毒s蛋白的重组新城疫病毒及其制备方法与应用
CN113943714A (zh) 一种猫杯状病毒毒株及其应用
CN107158369B (zh) 一种使用构建的基因vii型新城疫病毒弱毒株制备的疫苗
CN113897376B (zh) 一种hn蛋白突变的基因vii型新城疫病毒重组疫苗株
CN107058244B (zh) 一种p蛋白突变构建的基因vii型新城疫病毒弱毒株
CN112891528B (zh) 一种鸡传染性支气管炎疫苗株
CN112111467B (zh) 一种基因vii型新城疫标记疫苗株及其制备方法与应用
US11696947B2 (en) H52 IBV vaccine with heterologous spike protein
CN110904056B (zh) 一种传染性支气管炎病毒rH120-YZS1Δ5a及其构建方法和应用
CN114292823A (zh) 携带基因VII型新城疫病毒F和HN基因的重组LaSota疫苗株及其构建方法和应用
CN107164335B (zh) 一种基因vii型新城疫弱病毒株
KR101073991B1 (ko) 국내사육 닭에서 유행하는 신규한 b형 조류메타뉴모바이러스 sc1509주 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant